and mupirocin ointment. Patch testing with the North American Contact Dermatitis Group (NACDG) standard tray, corticosteroids, vehicles, preservatives, flavorings, corticosteroids, cosmetics ...

A 67-year-old patient with a personal history of systemic scleroderma and chronic renal failure and who had been in hemodialysis since 2004 presented with an itchy, erythematous, and desquamative ...

If you can already feel the moisture-sucking wind of the winter ahead, now is the time to drop this all-purpose salve into ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, to expand its dermatology portfolio.

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Pfizer showcased new treatments for atopic dermatitis, the leading type of eczema, at the 7th China International Import Expo ...

The new PDUFA target date is March 12, 2025. The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the ...

cream, 1% as a treatment for atopic dermatitis (AD) in adults and children two years of age and older. The new target date is March 12, 2025, revised from the original target action date of ...